Comparative Pharmacology
Head-to-head clinical analysis: KENALOG IN ORABASE versus KENALOG 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KENALOG IN ORABASE versus KENALOG 10.
KENALOG IN ORABASE vs KENALOG-10
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit fibroblast proliferation.
Triamcinolone acetonide is a synthetic corticosteroid with anti-inflammatory, immunosuppressive, and antiproliferative actions. It binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production (e.g., IL-1, IL-2, TNF-alpha). It also stabilizes lysosomal membranes and inhibits fibroblast proliferation.
Adjunctive treatment for inflammatory and ulcerative diseases of oral mucosa (e.g., aphthous ulcers, lichen planus)Topical corticosteroid for oral lesions
Inflammatory and allergic conditions (e.g., asthma, rheumatoid arthritis, systemic lupus erythematosus)Dermatologic diseases (e.g., psoriasis, atopic dermatitis, contact dermatitis)Intra-articular or soft tissue injection for osteoarthritis, bursitis, tendinitisOphthalmic conditions (e.g., uveitis, iritis, allergic conjunctivitis)Off-label: Keloid scars, hypertrophic scars, cystic acne, alopecia areata
Apply a thin layer to the affected area 2-4 times daily, after meals and at bedtime. Do not rub in; allow to form a film.
Intra-articular, intrabursal, or soft tissue injection: 10-40 mg (0.25-1 mL of 10 mg/mL) for large joints; 10 mg (0.25 mL) for small joints; repeat every 3-4 weeks if needed. Intralesional: 10-40 mg (0.25-1 mL) per lesion; maximum 1 mL per injection site; repeat every 1-2 weeks.
None Documented
None Documented
Terminal half-life approximately 2-5 hours following mucosal application.
Terminal elimination half-life is approximately 2–5 hours for triamcinolone acetonide. However, the duration of action is prolonged due to the crystalline suspension's slow dissolution from the injection site, resulting in a prolonged residence time and effects lasting weeks. The plasma half-life primarily reflects systemic clearance after absorption.
Hepatic metabolism primarily via CYP3A4; undergoes reduction, oxidation, and conjugation.
Primarily hepatic via CYP3A4. Triamcinolone acetonide is metabolized to inactive metabolites, mainly 6β-hydroxytriamcinolone acetonide. Less than 1% excreted unchanged in urine.
Primarily hepatic metabolism; metabolites excreted renally (~75%) and in feces (~10%).
Primarily hepatic metabolism (~80%) followed by renal excretion of inactive metabolites (glucuronide and sulfate conjugates). Unchanged triamcinolone acetonide accounts for <5% of urinary recovery. Biliary/fecal excretion is minor.
Approximately 70-90% bound to corticosteroid-binding globulin and albumin.
Approximately 68–79% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin (CBG).
Estimated Vd of 1.5-3.5 L/kg, reflecting extensive tissue distribution.
Apparent volume of distribution is approximately 0.2–0.5 L/kg. This low Vd reflects limited extravascular distribution and high protein binding.
Systemic bioavailability via oral mucosa is low but not precisely quantified; local delivery is the primary route.
Intramuscular administration: 100% bioavailable (by design, as it is a depot formulation). Oral: Not applicable (not available). Intra-articular: Bioavailability is essentially 100% at the local site, but systemic absorption is limited; peak plasma concentrations are lower than after IM injection due to slow release.
No dose adjustment required for renal impairment.
No specific GFR-based dose adjustment required; use caution in severe renal impairment due to potential systemic effects.
No dose adjustment required for hepatic impairment.
No specific Child-Pugh-based dose adjustment; use caution in severe hepatic impairment due to potential corticosteroid-related adverse effects.
Safety and efficacy in pediatric patients have not been established; use only if clearly needed and use the smallest effective amount.
Intra-articular: 5-20 mg for large joints, 2.5-10 mg for small joints; intralesional: 2.5-10 mg per lesion; dose based on body surface area (BSA) and severity; not recommended for children under 12 unless directed by specialist.
Use the smallest effective amount for the shortest duration due to increased potential for systemic effects with age.
Initiate at lower end of dosing range (e.g., 10-20 mg intra-articular); monitor for increased susceptibility to corticosteroid side effects, including osteoporosis, hyperglycemia, and immunosuppression; avoid repeated injections in weight-bearing joints.
No FDA black box warning.
No FDA boxed warning specific to KENALOG-10; however, corticosteroids in general have warnings for increased mortality in certain conditions (e.g., systemic fungal infections, cerebral malaria). Avoid live vaccines during therapy.
["Immunosuppression may increase susceptibility to infections","Adrenal suppression with prolonged use","Avoid use in patients with known hypersensitivity to corticosteroids","Use with caution in patients with diabetes, hypertension, or osteoporosis","Do not swallow or apply to large areas of skin"]
["Hypothalamic-pituitary-adrenal (HPA) axis suppression with prolonged use or high doses","Increased susceptibility to infections and masking of infection signs","Cushing's syndrome, osteoporosis, avascular necrosis, myopathy, peptic ulcer, pancreatitis","Ophthalmic effects: cataracts, glaucoma, central serous chorioretinopathy","Psychiatric disturbances (euphoria, depression, psychosis)","Fetal harm (Pregnancy Category C); use only if benefit outweighs risk"]
["Systemic fungal infections","Hypersensitivity to triamcinolone or any component of the formulation","Viral or bacterial infections of the oral mucosa (e.g., herpes simplex)"]
["Systemic fungal infections","Hypersensitivity to triamcinolone or any component","Intrathecal administration (risk of arachnoiditis, neurological injury)","Live or live-attenuated vaccines (theoretical risk of disseminated infection)","Relative: Active tuberculosis, untreated bacterial/viral infections, recent vaccination"]
Data Pending Review
Data Pending Review
Avoid hot, spicy, or acidic foods during treatment as they may irritate the lesion. No specific food-drug interactions are known.
No specific food interactions. Avoid excessive salt intake, as corticosteroids can cause sodium and water retention. Grapefruit and grapefruit juice may increase systemic absorption if used topically or after injection; limit intake.
Triamcinolone acetonide (KENALOG IN ORABASE) is a corticosteroid. Systemic absorption from oral mucosal application is minimal but may occur. In first trimester, corticosteroid use is associated with a small increased risk of oral clefts (odds ratio ~1.3-3.4). Second and third trimester use may cause fetal adrenal suppression, intrauterine growth restriction, and preterm birth if significant systemic exposure occurs. Topical use with minimal absorption is generally considered low risk, but theoretical risks persist.
First trimester: increased risk of cleft palate (odds ratio 1.3-6.7). Second/third trimester: fetal growth restriction, adrenal suppression, hypothalamic-pituitary-adrenal axis suppression. Chronic use: low birth weight, preterm birth.
Triamcinolone acetonide is excreted into human breast milk in low amounts following systemic administration. The milk-to-plasma ratio is unknown for topical oral formulation, but due to low systemic absorption, concentrations are expected to be negligible. No adverse effects on the infant have been reported with topical corticosteroids. Caution is advised with prolonged or extensive use.
Triamcinolone acetonide (KENALOG-10) is excreted in human milk in low amounts. M/P ratio not established. Potential for adrenal suppression in infant. Use with caution during breastfeeding, especially at high doses or prolonged therapy.
No specific dose adjustment needed for standard use of KENALOG IN ORABASE during pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered clearance) are not clinically relevant due to minimal systemic absorption. Avoid excessive application or use on large mucosal areas to minimize systemic exposure.
No specific dose adjustment required for triamcinolone acetonide during pregnancy. Use lowest effective dose. Monitor for increased corticosteroid requirements due to pregnancy-induced changes. Consider alternate corticosteroids (e.g., prednisolone) if systemic therapy needed due to better placental metabolism.
Category C
Category C
Apply a thin layer to the lesion after meals and at bedtime. Do not rub in; allow to form a film. Avoid use on infected lesions unless antifungal/antibacterial coverage is provided. Use with caution in patients with diabetes, hypertension, or peptic ulcer disease due to potential systemic absorption.
Kenalog-10 (triamcinolone acetonide 10 mg/mL) is a potent corticosteroid for intra-articular, intralesional, or soft tissue injection. Avoid injection into infected joints or unstable joints. Post-injection flare (crystal-induced synovitis) may occur. Do not administer IV, IM, or intradermally. Use caution in patients with diabetes, as it can elevate blood glucose. Limit frequency to every 3-4 weeks per joint to avoid cartilage damage.
Apply a thin layer to the affected area after meals and at bedtime.Do not rub or massage the paste into the tissue.Avoid eating or drinking immediately after application to allow the paste to adhere.Do not use if you have a fungal or bacterial infection in the mouth unless directed.Notify your doctor if symptoms persist beyond 7 days or if swelling occurs.
Do not exercise or overuse the injected joint for 48 hours after the injection to allow the medication to work.Report signs of infection (increased pain, redness, swelling, fever) or allergic reactions (rash, difficulty breathing).You may experience a temporary increase in pain (steroid flare) which usually resolves within 24-48 hours.Avoid alcohol consumption for at least 24 hours after injection to reduce bleeding risk.Tell your doctor if you have diabetes, as this medication can increase blood sugar levels.